Education
About Us
Working with TipRanks
Follow Us
OncoArendi Therapeutics SA (DE:1B1)
FRANKFURT:1B1
Total Valuation
OncoArendi Therapeutics SA has a market cap or net worth of €35.95M. The enterprise value is €193.10M.
Market Cap€35.95M
Enterprise Value€193.10M
Share Statistics
OncoArendi Therapeutics SA has 20,603,155 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,603,155
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
OncoArendi Therapeutics SA’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -30.34%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-30.34%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-306.74K
Employee Count102
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of OncoArendi Therapeutics SA is ―. OncoArendi Therapeutics SA’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value1.97
Price to FCF0.00
Price to Operating Cash Flow-5.34
PEG Ratio―
Income Statement
In the last 12 months, OncoArendi Therapeutics SA had revenue of 0.00 and earned -31.29M in profits. Earnings per share was -1.55.
Revenue0.00
Gross Profit0.00
Operating Income-33.61M
Pretax Income-31.29M
Net Income-31.29M
EBITDA-27.37M
Earnings Per Share (EPS)-1.55
Cash Flow
In the last 12 months, operating cash flow was -28.69M and capital expenditures -17.86M, giving a free cash flow of -46.55M billion.
Operating Cash Flow-28.69M
Free Cash Flow-46.55M
Free Cash Flow per Share-2.26
Dividends & Yields
OncoArendi Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.22
52-Week Price Change-46.03%
50-Day Moving Average1.72
200-Day Moving Average1.85
Relative Strength Index (RSI)52.28
Average Volume (3m)0.00
Important Dates
OncoArendi Therapeutics SA upcoming earnings date is Sep 30, 2025, Before Open (Confirmed).
Last Earnings DateApr 30, 2025
Next Earnings DateSep 30, 2025
Ex-Dividend Date―
Financial Position
OncoArendi Therapeutics SA as a current ratio of 9.82, with Debt / Equity ratio of 6.81%
Current Ratio9.82
Quick Ratio9.82
Debt to Market Cap0.00
Net Debt to EBITDA0.40
Interest Coverage Ratio-356.66
Taxes
In the past 12 months, OncoArendi Therapeutics SA has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
OncoArendi Therapeutics SA EV to EBITDA ratio is -7.05, with an EV/FCF ratio of -2.39.
EV to Sales0.00
EV to EBITDA-7.05
EV to Free Cash Flow-2.39
EV to Operating Cash Flow-3.39
Balance Sheet
OncoArendi Therapeutics SA has €40.66M in cash and marketable securities with €6.69M in debt, giving a net cash position of €33.97M billion.
Cash & Marketable Securities€40.66M
Total Debt€6.69M
Net Cash€33.97M
Net Cash Per Share€1.65
Tangible Book Value Per Share€2.45
Margins
Gross margin is -23697.55%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-23697.55%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for OncoArendi Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―